Advanced Lipid Panel (ApoB, Lp(a), LDL Particle) — Diagnostics & Biomarker Testing
Beyond standard cholesterol: ApoB quantifies total atherogenic particle burden, Lp(a) identifies genetic cardiovascular risk affecting 20% of the population — both causally linked to cardiovascular disease.
Overview
Standard lipid panels (total cholesterol, LDL-C, HDL-C, triglycerides) miss critical cardiovascular risk in a substantial portion of patients. ApoB (apolipoprotein B) is a protein present on every atherogenic particle (LDL, IDL, VLDL, Lp(a)) — one ApoB per particle — making it the most accurate measure of total atherogenic burden, superior to LDL-C. Multiple Mendelian randomization studies confirm ApoB causally drives cardiovascular events; ApoB targets have been adopted in Canadian guidelines and are endorsed by Peter Attia, Andrew Huberman, and most lipidologists. Lp(a) (lipoprotein(a)) is a genetically-determined LDL-like particle that causes approximately 10-15% of all cardiovascular events and is elevated in 20% of the global population — affecting 1.5 billion people. Standard LDL panels do not measure Lp(a) or ApoB. Homocysteine (> 15 μmol/L associated with 2x cardiovascular risk) and ApoA1 round out the advanced panel. Marek Health, Ulta Lab Tests, and InsideTracker offer these tests directly to consumers.
Indications
- Comprehensive cardiovascular risk assessment beyond standard lipids
- Identification of genetically elevated Lp(a) (20% of population)
- Statin therapy monitoring (ApoB target, not LDL-C)
- PCSK9 inhibitor candidacy assessment
- Familial hypercholesterolemia screening
- Evaluation of patients with 'normal' LDL but cardiovascular disease
Mechanism of Action
Each LDL, IDL, VLDL, and Lp(a) particle carries exactly one ApoB molecule — making ApoB a perfect stoichiometric count of total atherogenic particles independent of their cholesterol content
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Advanced Lipid Panel | Fasting blood draw | Annually or after lipid-lowering therapy changes | Test at least 4-6 weeks after starting/changing statin or PCSK9 inhibitor for meaningful result |
Evidence Grade
GRADE B
Safety & Contraindications
- Blood draw with standard venipuncture risks (bruising, hematoma)
- Results require interpretation with clinical context — elevated Lp(a) cannot currently be treated with standard lipid-lowering agents (statins do not lower Lp(a))
- Lp(a) result can cause significant psychological distress given its genetic basis and limited treatment options (though RNA therapeutics targeting Lp(a) are in late-stage trials)